Johnson & Johnson recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for lumateperone (Caplyta®), based on long-term data supporting its safety and efficacy in preventing relapse in schizophrenia. Caplyta (42 mg) is a once-daily oral atypical antipsychotic currently approved [...]
A study of 1.5 million UK adults found that autoimmune diseases are linked to a nearly twofold increase in the risk for mood disorders such as depression, anxiety, and bipolar disorder compared with the general population. The research, published in BMJ Mental Health, highlights the importance of regular mental health screenings [...]
Semaglutide, a medication for type 2 diabetes (T2D), is associated with a 20%-46% reduced risk for Alzheimer's disease-related dementia compared with other antidiabetic drugs. A study analyzed electronic health records of over 1.7 million US adults with T2D, focusing on dementia diagnoses over three years. Semaglutide showed a stronger protective [...]
An international panel of 89 experts from 17 countries has developed new guidelines—Reporting of Setting in Psychedelic Clinical Trials (ReSPCT)—to standardize how psychedelic clinical trials report 'set and setting,' the mindset and environment in which psychedelic experiences occur. Published in Nature Medicine, the guidelines outline 30 variables across four key [...]
A Phase 3 clinical trial has shown that LYN-005—a once-weekly oral capsule formulation of risperidone—achieves comparable bioavailability and symptom control to daily dosing in patients with schizophrenia or schizoaffective disorder. Conducted at five sites across the U.S. and enrolling 83 participants, the study was stopped early following positive interim results. [...]
Psychological therapy has been shown to significantly alleviate depression and anxiety in stroke survivors, particularly when initiated within six months of the stroke event. In a study involving over 7,000 adults in England, 71% experienced a reliable improvement in symptoms, while 49% achieved reliable recovery. Patients who began therapy more [...]
A Phase 3 clinical trial of COMP360, a synthetic formulation of psilocybin, showed a significant reduction in symptoms of treatment-resistant depression. Conducted at 32 sites across the U.S. with 258 participants, the study found that a single 25 mg dose led to greater symptom improvement on the Montgomery-Åsberg Depression Rating [...]
Two new studies examining mental health risks postpartum were published online in the American Journal of Psychiatry in conjunction with Maternal Mental Health Awareness Month and the 2025 Annual Meeting of the American Psychiatric Association (APA). One study sought to estimate the risk of postpartum depression in people without a [...]
A novel blood test that detects a key biomarker for Alzheimer’s disease (AD) could help physicians more accurately determine the presence and track disease progression. The test measures levels of the protein MTBR-tau243 — microtubule-binding region of tau containing the residue 243 — a biomarker of tau tangles in the [...]
Neurocrine Biosciences presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia (TD) among most patients treated with once-daily valbenazine (Ingrezza) capsules, at the 2025 Psychiatry Update Conference in Chicago.1 The conference was first reported in Psychiatric Times "These findings further establish Ingrezza as a [...]